Early Reduction of FeNO on Anti‐ IL5 Biologics Is Associated With Clinical Remission of Severe Asthma
Allergy · 2025
DOI: 10.1111/all.16425 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, 2025. Verfasst von Marianne Baastrup Soendergaard und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Copenhagen University Hospital-Bispebjerg, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Asthma, Nitric Oxide, Biological Products, Interleukin-5. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: DSAR is funded by grants from GlaxoSmithKline, Novartis, AstraZeneca, Teva and Sanofi.
Abstract (Originalsprache)
Background
In patients with severe asthma, treatment with anti‐interleukin‐5 (IL‐5) biologics can lead to a reduction in fractional exhaled nitric oxide (FeNO) in some patients. The clinical implications of varying FeNO responses to anti‐IL‐5 biologics remain unclear. This study aims to categorise patients based on their FeNO response to anti‐IL‐5 biologics and evaluate the association of these categories with clinical outcomes.
Methods
We used the Danish Severe Asthma Register (DSAR) to identify the early FeNO response profiles in patients receiving anti‐IL5 biologics. We defined FeNO responders as patients with elevated FeNO levels at baseline and a decrease corresponding to the minimal clinically important difference (MCID) at 4 months of follow‐up and FeNO non‐responders as those who did not experience a decrease.
Results
We identified 403 patients on anti‐IL5 treatment in DSAR, and 265 (66%) had elevated FeNO levels at baseline. After 4 months of treatment, 151 (57%) patients showed a significant decrease in FeNO levels, and 114 (43%) did not. FeNO responders were more likely to achieve clinical remission of asthma (34% vs. 19%, p = 0.01, OR 2.11, CI 1.04, 5.18, p = 0.03) than FeNO non‐responders after 12 months of treatment. The higher remission rates in FeNO responders mainly reflected a higher rate of normalisation of lung function.
Conclusions
FeNO levels were reduced after anti‐IL5 treatment in a significant proportion of patients treated with anti‐IL5, and this was associated with clinical remission. Early FeNO response to anti‐IL5 could potentially be used as a biomarker to guide management decisions with biologics towards remission of disease in severe asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Copenhagen University Hospital-Bispebjerg, Copenhagen, Denmark.
- Centre for Clinical Research and Prevention, Frederiksberg Hospital, Copenhagen, Denmark.
- Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark.
- Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.
- Department of Respiratory Medicine, Odense University Hospital, Odense, Denmark.
- Allergy Clinic, Gentofte University Hospital, Hellerup, Denmark.
ORCID-Profile: Marianne Baastrup Soendergaard, Kjell Erik Julius Håkansson, Celeste Porsbjerg
Förderung
- DSAR is funded by grants from GlaxoSmithKline, Novartis, AstraZeneca, Teva and Sanofi
Zitieren
APA
Soendergaard, M. B., Hansen, S., Håkansson, K. E. J., von Bülow, A., Bjerrum, A. S., Schmid, J. M., Johansson, S. L., Rasmussen, L. M., Johnsen, C. R., Bertelsen, B. B., Krogh, N. S., Hilberg, O., Ulrik, C. S., & Porsbjerg, C. (2025). Early Reduction of FeNO on Anti‐ IL5 Biologics Is Associated With Clinical Remission of Severe Asthma. Allergy. https://doi.org/10.1111/all.16425
Vancouver
Soendergaard MB, Hansen S, Håkansson KEJ, von Bülow A, Bjerrum AS, Schmid JM, et al. Early Reduction of FeNO on Anti‐ IL5 Biologics Is Associated With Clinical Remission of Severe Asthma. Allergy. 2025. doi:10.1111/all.16425
BibTeX
@article{Soendergaard2025,
author = {Soendergaard, Marianne Baastrup and Hansen, Susanne and Håkansson, Kjell Erik Julius and von Bülow, Anna and Bjerrum, Anne-Sofie and Schmid, Johannes Martin and Johansson, Sofie Lock and Rasmussen, Linda Makowska and Johnsen, Claus Rikard and Bertelsen, Barbara Bonnesen and Krogh, Niels Steen and Hilberg, Ole and Ulrik, Charlotte Suppli and Porsbjerg, Celeste},
title = {Early Reduction of FeNO on Anti‐ IL5 Biologics Is Associated With Clinical Remission of Severe Asthma},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.16425}
}
EUVIMED